NanoSyrinx has appointed Thomas Farrell as chief executive officer and director, succeeding founder Joe Healey, who will remain involved to provide continuity and scientific leadership as the company advances its intracellular therapeutics platform.

The Coventry-based synthetic biology company develops Nanosyringes, a platform technology designed to enable precise delivery of biologic therapeutics directly into the cytosol of target cells. The platform is intended to address challenges in intracellular drug delivery and support the development of first-in-class biotherapeutics.

Farrell brings over 25 years of leadership experience in biotherapeutics, including founding and leading multiple biotechnology companies through early-stage discovery, clinical trials, and commercial development. He has guided companies through financing, strategic partnerships, and growth initiatives in oncology, immunology, and rare monogenic diseases. Most recently, he served as president of Oricell Therapeutics, a clinical-stage CAR-T company, and interim CEO for several cell and gene therapy ventures.

Edwin Moses, chairman of NanoSyrinx, said Farrell’s appointment aligns with the company’s next stage of growth. He said: “Tom’s exceptional track record in progressing therapies from concept to clinic, combined with his global perspective, will be invaluable as NanoSyrinx moves from platform development to establishing a robust clinical pipeline. His leadership is perfectly aligned with our mission to advance intracellular drug delivery, providing us with the strategic vision and hands-on expertise to maximise the potential of our novel Nanosyringe platform to develop new therapies for the treatment of complex diseases.”

Moses also acknowledged the contribution of founder Joe Healey. He said: “On behalf of the Board, I would like to sincerely thank Joe, whose vision and dedication as founder and CEO have been key to progressing NanoSyrinx to this exciting phase of development.”

Farrell said he was joining NanoSyrinx at an important stage in the company’s development. He said: “The Nanosyringe platform has the potential to deliver a completely new class of medicines benefiting from precise biologic delivery into the cytosol of target cells. I am honoured to work with the team to move from platform development to building a clinical therapeutic pipeline and bringing transformative medicines to patients. With our unique validated technology, solid foundations, and support from an exceptional syndicate of investors and Board members, alongside a growing leadership team, NanoSyrinx is well-positioned to pursue new partnerships and drive value as we enter our next stage of growth.”

NanoSyrinx is now transitioning from platform development to building a differentiated pipeline of Nanosyringe-enabled therapeutics. The company aims to advance intracellular biologic medicines that could address challenging diseases where traditional approaches have limited effectiveness.